[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombopenia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100591387","research-for-plasma-biomarkers-associated-with-fatigue-in-thrombocytopenic-patients-100591387",false,"NCT06979765","Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients","FAGPLAQ","Inclusion criteria for patients (adults or minors):\n\n* Patients with constitutional or autoimmune (chronic or persistent ITP with last treatment administration ≥ 3 weeks) thrombocytopenia (platelet count \\\u003C 150×109\u002FL) already diagnosed\n* patient not being treated and not receiving serotonin reuptake inhibitor (SSRI) or norepinephrine (SNRI) or antithrombotic treatments (antiplatelet or anticoagulant) in the 10 days prior to inclusion\n* affiliation to social security (beneficiary or assignee)\n* patient followed in consultation in one of the recruiting haematology departments\n* Patient (or parent) having received a detailed explanation of the research project and having consent by signing the consent form before any research-specific procedure\n\nInclusion criteria for healthy volunteers:\n\n* Age- (± 5 years) and sex-matched healthy adult controls\n* Non-thrombocytopenic patients and not receiving antithrombotic, SNRI or SSRI therapy or if applicable, last treatment ≥ 10 days\n* affiliation to social security (beneficiary or assignee)\n* adults who received a detailed explanation of the research project and having consent by signing the consent form before any research-specific procedure\n\nNon inclusion criteria (adults and minors):\n\n* Adult patients under legal protection (guardianship or curatorship) Thrombocytopenic patients treated with antithrombotics, serotonin reuptake inhibitors (SSRIs) or noradrenaline reuptake inhibitors (SNRIs)\n* Minor patients weighing less than 20 kg\n\nNon inclusion criteria for healthy adult controls:\n\n* Healthy adult volunteers under legal protection (guardianship, curatorship or safeguard of justice).\n* Pregnant women",true,"ALL","8 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"NA","Thrombocytopenia is a clinical problem defined by a platelet count lower than 150×10⁹\u002FL. It can be linked to various pathologies of central origin, such as decreased platelet production in the bone marrow, or peripheral origin with increased platelet destruction through autoimmune mechanisms, increased splenic sequestration, or excessive platelet consumption. Significant fatigue is often reported in association with thrombocytopenia, but its underlying pathophysiology remains unclear. One hypothesis is the role played by neurotrophic factors contained in platelets and released into the circulation following their activation, in particular the Brain-Derived Neurotrophic Factor (BDNF), which promotes the survival, growth, differentiation, and plasticity of neurons in both the central and peripheral nervous systems. Consequently, BDNF plays a key role in long-term memory, intellectual abilities, and neuroprotection.\n\nIn this context, this project aims to confirm whether platelet-origin neurotrophic biomarkers could explain the fatigue experienced by thrombocytopenic patients and whether it depends on the etiology of the thrombocytopenia.",[27],"Thrombopenia",[27],"RECRUITING","2026-02-02",{"date":32,"type":33},"2026-02-03","ACTUAL",{"date":35,"type":33},"2025-03-26",{"date":37,"type":21},"2028-06-26",{"name":39,"class":40},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":41},"100582913","study-of-the-prevalence-of-acid-sphingomyelinase-deficiencyniemann-pick-ab-and-b-disease-in-patients-with-diffuse-interstitial-lung-disease-100582913","NCT06869499","Study of the Prevalence of Acid Sphingomyelinase Deficiency\u002FNiemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease","Niemann-PID: Study of the Prevalence of Acid Sphingomyelinase Deficiency\u002FNiemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease","Niemann-PID","Inclusion Criteria:\n\n1. Interstitial lung disease with ground-glass lesions on a chest CT scan certified by a pneumologist\u002Fradiologist or internist.\n2. At least one of the following criteria :\n\n   * Splenomegaly (palpable spleen or craniocaudal length ≥ 13 cm)\n   * Splenectomy\n   * Thrombocytopenia (platelets \\\u003C 150 G\u002FL)\n   * Low HDL-cholesterol (\\\u003C0.4 g\u002Fl or 1.03 mmol\u002Fl)\n   * Notion of parental consanguinity\n3. Have given their written informed consent, in accordance with regulations.\n4. Affiliated to the social security system or entitled beneficiary (excluding AME).\n\nExclusion Criteria:\n\n1. Inability to understand the information provided.\n2. Under guardianship, curatorship or legal protection.\n3. Under restraint or deprived of liberty by judicial or administrative decision.","15 Years","60 Years",{"count":53,"type":21},200,[24],"The goal of this clinical trial is to optimise and facilitate screening for Acid SphingoMyelinase Deficiency (ASMD) disease, by evaluating acid sphingomyelinase activity and, where appropriate, LysoSM levels in a cohort of 200 participants with diffuse interstitial lund disease (ILD) at risk of developing ASMD disease.\n\nILD is common in the general population, so in order to limit the number of differential diagnoses, the population to be studied will be restricted to participants aged between 15 years and 3 months and 60 years, with ILD plus ground-glass opacities on chest CT scan certified by a pulmonologist\u002Fradiologist or internist, AND splenomegaly or splenectomy, and\u002For thrombocytopenia, and\u002For low HDL cholesterol, and\u002For parental consanguinity which increase the sensitivity of ASMD screening.\n\nIn this clinical trail, two procedures are added, participants will be asked for :\n\n* a blood sample to measure the acid sphingomyelinase enzyme activity and LysoSM, if required.\n* a follow-up visit at 6 months",[57,58,27,59,60],"Splenomegaly","Splenectomy","Interstitial Lung Disease (ILD)","Hypocholesterolemia",[62,63,64,65,66,67,68,69,70],"Acid sphingomyelinase deficiency","Ground glass lesions","Niemann Pick A\u002FB, B","lysoSM","smpd1","splenomegaly","interstitial lung disease","screening","acid sphingomyelinase","NOT_YET_RECRUITING","2025-05-14",{"date":74,"type":33},"2025-05-18",{"date":76,"type":21},"2025-05",{"date":78,"type":21},"2029-03-01",{"name":80,"class":40},"Wladimir MAUHIN, Dr",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":41},"100573356","phase-2-herombopag-for-the-prevention-of-radio-chemotherapy-induced-thrombocytopenia-in-cervical-cancer-100573356","NCT06745219","Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer","Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer: A Single-arm Phase II Clinical Trial","Inclusion Criteria:\n\n1. Volunteer to participate in the trial and sign the informed consent\n2. Pathologically or cytologically confirmed cervical cancer\n3. aged 18 years or older\n4. ECOG performance score 0-1\n5. Stage IB3-IVA according to 2018 FIGO stage\n6. Patients receiving cisplatin-contained two-drug every-three week chemotherapy; minimum PLT value of the last chemotherapy \\\u003C50×109\u002FL, or ≥50 ×109\u002FL, but \\\u003C75×109\u002FL, meeting at least one high risk factor for bleeding: previous bleeding history; receiving cisplatin, gemcitabine, cytarabiine, anthracycline chemotherapy; combination of targeting or chemotherapy drugs likely to cause thrombocytopenia; tumor bone marrow infiltration; receiving radiotherapy, such as long bone or flat bone (pelvic or sternum)\n7. Survival expected to be ≥12 weeks, and can be treated with the concurrent chemotherapy regimen for at least one cycle\n8. Participants of reproductive age who agree to use reliable contraceptive methods throughout the study period (including male or female condoms, contraceptive foam, contraceptive gel, contraceptive film, contraceptive paste, contraceptive suppository, abstinence from sex, and insertion of an IUD); Female subjects who have undergone hysterectomy, bilateral salpingectomy, bilateral tubal ligation or more than 1 year postmenopausal and male subjects who have undergone bilateral vasectomy or ligation are excluded\n9. Participants can be treated with thrombopoietic drugs determined by researchers\n\nExclusion Criteria:\n\n1. Participants with other diseases of hematopoietic system, including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome\n2. Participants with thrombocytopenia occurred within the last 6 months due to causes other than CTIT, including but not limited to chronic liver disease, hypersplenism, infection\n3. Bone marrow invasion or metastasis\n4. History of severe cardiovascular disease within the last 6 months, such as congestive heart failure (NYHA heart function score III-IV), arrhythmias known to increase the risk of thromboembolism such as atrial fibrillation, after coronary stenting, angioplasty, and para-coronary transplantation, etc\n5. History of any arterial or venous thrombosis within the last 6 months\n6. Severe bleeding within 2 weeks, such as gastrointestinal or central nervous system bleeding, vaginal bleeding, etc\n7. Neutrophil absolute value \\\u003C1.5×109\u002FL, hemoglobin \\\u003C80g\u002FL, PLT\\\u003C90× 109\u002FL\n8. Significantly abnormal liver function :TBIL\\>1.5ULN(upper limit of normal), \\>3ULN for patients known to have Gilbert syndrome; ALT\\>2.5ULN or AST\\>2.5ULN\n9. Abnormal renal function: serum creatinine ≥1.5ULN or eGFR≤60 ml\u002Fmin(Cockcroft-Gault formula)\n10. Had received platelet infusion within 3 days\n11. known or expected allergy or intolerance to the active ingredient or excipient of hetropopar ethanolamine tablets\n12. HIV infected\n13. Pregnant or lactating women\n14. Participated in clinical trials of any other investigational drug or device within 28 days\n15. Inability to swallow, inflammatory bowel disease, or uncontrollable nausea, vomiting, diarrhea, or other gastrointestinal disorders that severely affect the administration and absorption of medications\n16. With a high risk for participants' safety or other conditions that may affect the efficacy evaluated by investigators","FEMALE","18 Years",{"count":91,"type":21},30,[93],"PHASE2","Exploring and evaluating the efficacy of herombopag in preventing thrombocytopenia due to radiotherapy for cervical cancer",[27,96,97,98],"Cervical Cancer","Radiotherapy Side Effect","Chemotherapeutic Toxicity","2024-12-17",{"date":101,"type":33},"2024-12-20",{"date":103,"type":21},"2025-01-01",{"date":105,"type":21},"2025-07-30",{"name":107,"class":40},"Peking University Cancer Hospital & Institute"]